326 related articles for article (PubMed ID: 16568235)
1. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance.
Balaraman Y; Limaye AR; Levey AI; Srinivasan S
Cell Mol Life Sci; 2006 Jun; 63(11):1226-35. PubMed ID: 16568235
[TBL] [Abstract][Full Text] [Related]
2. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
Arafa RK; Elghazawy NH
Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target.
Mandlik DS; Mandlik SK; S A
Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363
[TBL] [Abstract][Full Text] [Related]
4. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
5. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
7. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
[TBL] [Abstract][Full Text] [Related]
8. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
9. Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach.
Sharma V; Chander Sharma P; Reang J; Yadav V; Kumar Tonk R; Majeed J; Sharma K
Bioorg Chem; 2024 Jun; 147():107378. PubMed ID: 38643562
[TBL] [Abstract][Full Text] [Related]
10. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
11. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
14. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
[TBL] [Abstract][Full Text] [Related]
15. Wnt signaling function in Alzheimer's disease.
De Ferrari GV; Inestrosa NC
Brain Res Brain Res Rev; 2000 Aug; 33(1):1-12. PubMed ID: 10967351
[TBL] [Abstract][Full Text] [Related]
16. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
[TBL] [Abstract][Full Text] [Related]
17. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
18. Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer's pathologies?
Manoharan SD; Abdul Hamid H; Md Hashim NF; Cheema MS; Chiroma SM; Mustapha M; Mehat MZ
Brain Res; 2024 Apr; 1829():148793. PubMed ID: 38309553
[TBL] [Abstract][Full Text] [Related]
19. GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
Sayas CL; Ávila J
Cells; 2021 Mar; 10(4):. PubMed ID: 33804962
[TBL] [Abstract][Full Text] [Related]
20. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?
Martinez A; Perez DI
J Alzheimers Dis; 2008 Oct; 15(2):181-91. PubMed ID: 18953107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
